Human-based glucagon-like peptide-1 receptor agonist (GLP-1 RA) such as Semaglutide (compounded), Wegovy and Ozempic are prescribed as a means of an adjunct for weight management. By mimicking a hormone in the body, Semaglutide increases insulin secretion while slowing down how fast your stomach empties food. This suppresses your appetite, so you feel full longer, helping you eat less and lose weight.
The drug was initially approved in 2017 at a lower dose to help control blood sugar in Type 2 diabetes. People taking semaglutide for blood sugar control lose weight as an additional benefit. After studying a higher amount of the medication in people without Type 2 diabetes, the FDA approved semaglutide for weight loss in qualified adults.
Semaglutide mimics a hormone called glucagon-like peptide-1 (or GLP-1) that targets areas in the brain that regulate appetite and food intake. Your digestive tract releases this incretin hormone after you’ve eaten a meal, lowering your blood sugar by triggering insulin release to block sugar production. Doing so helps you eat less and lose one to two pounds per week. And while a reduced-calorie meal plan increases the rate at which you lose and keep off weight, dieting is not required to lose weight on Semaglutide.
To determine whether you are a good candidate for weight loss with semaglutide injections, Our nurse practitioner will assess the extent of your being overweight. Adults can use semaglutide with a body mass index (or BMI) greater than or equal to 30. Alternatively, you may be a candidate for semaglutide weight loss if your BMI is 27 and you have at least one of the following weight-related conditions:
Our weight loss program with semaglutide is combined with lifestyle changes, including a healthy diet and exercise. However, as these measures are highly recommended, its is not necessary to lose weight with semaglutide injections.
Semaglutide is the first of its kind as a safe and highly effective hormone-based weight loss medication.
Some of the health benefits associated with Semaglutide include the following:
In clinical trials, Semaglutide helped most recipients lose 10% of their body weight. More than half of them reduced their weight by 15%, the amount that most healthcare professionals say can help reduce the risk for future chronic illnesses.
Gastrointestinal (or GI) side effects are most common when taking this medication, especially after increasing your dose. The most common side effects include the following:
Tirzepatide has been making waves for its potential as a weight loss injection. In the realm of obesity management, this dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist is showing promise in not only addressing type 2 diabetes but also in facilitating significant weight loss.
Tirzepatide's mechanism of action involves its interaction with both GIP and GLP-1 receptors. These receptors play vital roles in regulating glucose metabolism and controlling appetite. By modulating these pathways, tirzepatide aids in blood sugar management, reduces glucagon production, and fosters a sense of satiety, contributing to weight loss.
Significant Weight Loss: Clinical trials have demonstrated that Tirzepatide can lead to substantial weight loss in participants. This makes it a potentially effective option for individuals with obesity who have been unsuccessful with other weight loss interventions.
Improved Glucose Control: Tirzepatide is designed as a dual GIP and GLP-1 receptor agonist, which helps regulate blood sugar levels. This is particularly beneficial for individuals with type 2 diabetes, as it can contribute to better glycemic control.
Appetite Suppression: The medication's action on GIP and GLP-1 receptors may contribute to appetite suppression. This can lead to reduced food intake and may help individuals make healthier food choices, aiding in long-term weight management.
Enhanced Satiety: By promoting a sense of fullness, Tirzepatide may help individuals feel satisfied with smaller portions of food. This can be a valuable aspect of weight loss, as it may contribute to a decrease in overall caloric intake.
Potential Cardiovascular Benefits: Some GLP-1 receptor agonists, in general, have shown cardiovascular benefits. While more research is needed, Tirzepatide's dual action on GIP and GLP-1 receptors raises the possibility of cardiovascular advantages beyond weight loss.
Favorable Safety Profile: Initial data suggests that Tirzepatide maintains a favorable safety profile. As with any medication, individual responses can vary, but the observed benefits in terms of weight loss and glucose control are encouraging.
**IV hydration services provided have not been evaluated by the Food and Drug administration. These products are not intended to diagnose, treat, cure, or prevent any disease. The material on this website is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any therapy program. All therapies are specific formulations prepared by Revive and Thrive Optimal Wellness Solutions.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.